Novo Nordisk A/s

Niels Christian Kaarsholm

Svend Havelund

Helle Birk Olsen

Ib Jonassen

Jan Markussen

Kjeld Madsen

Svend Ludvigsen

Jakob Brandt

Per Hertz Hansen

Peter Kurtzhals

Liselotte Bjerre Knudsen

Per Olaf Huusfeldt

Thomas Borglum Kjeldsen

Per Franklin Nielsen

Freddy Zimmerdahl Pedersen

Peter Madsen

Palle Jakobsen

Per Balschmidt

Nils Langeland Johansen

Lars Thim

Anders Klarskov Petersen

Dorte Bjerre Steensgaard

Susanne Bang

Soren Ostergaard

Peter Thygesen

Birgitte Koch Michelsen

Soren Erik Bjorn

Anette Sams Nielsen

S&oslash;ren Erik Bj&oslash;rn

The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated. The present invention further relates to methods for increasing the stability and/or solubility of insulin in insulin-containing formulations at a pH less than 7.0 by adding a salt of protamine to the insulin-containing formulations.

Soluble, stable insulin-containing formulations with a protamine salt

The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Derivatives of GLP-1 analogs

The present invention relates to novel ligands for the HisZnsites of the R-state insulin hexamer having the formula A-B-C-D-X (III), wherein: A is a chemical group which reversibly binds to a HisZnsites of an insulin hexamer; B is a linker; C is a fragment consisting of 0 to 5 neutral amino acids; D is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is &#x2014;OH, &#x2014;NHor a diamino group. The present invention also relates to R-state insulin hexamers comprising such ligands, and aqueous insulin preparations comprising such R-state insulin hexamers.

[object Object]

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

GLP-2 compounds, formulations, and uses thereof

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &#x3b1;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Insulin derivatives

Novel insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The novel insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences.

Method for making insulin precursors and insulin precursor analogs

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Stable, aqueous insulin formulations without phenol and m-cresol which are suitable for pulmonary delivery and for delivery when phenol and m-cresol are undesirable are disclosed. The formulations provide increased convenience for the patient.

Stable aqueous insulin preparations without phenol and cresol

Aqueous compositions comprising at least one peptide selected from glucagon, GLP-1, and analogues and derivatives thereof together with a stabilizing and solubilizing amount of at least one detergent, said detergent having at least 2 positive charges, at least 2 negative charges, or a combination of at least one positive charge and at least one negative charge.

Stabilized aqueous peptide solutions

The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.

Growing community of inventors

Vanlose, Denmark

Niels Christian Kaarsholm